NGT | IGT | NDM | PDM | |
---|---|---|---|---|
(n = 106) | (n = 140) | (n = 68) | (n = 108) | |
Basic characteristics | ||||
   Male, n (%) | 77 (72.6) | 108 (77.1) | 56 (82.4) | 86 (79.6) |
   Age, year | 64 ± 11 | 66 ± 10 | 63 ± 11 | 68 ± 9.* *** |
   Body-mass index, kg/m2 | 23.4 ± 3.0 | 23.5 ± 2.6 | 24.5 ± 2.7* ** | 24.2 ± 2.9* ** |
   Family history of IHD, n (%) | 30 (28.3) | 45(32.1) | 19 (27.9) | 26 (24.1) |
   History of smoking, n (%) | 80 (75.5) | 99(70.7) | 56 (82.4) | 79 (73.1) |
   Clinical history, n (%) | ||||
Hypertension, n (%) | 66 (62.3) | 82 (58.6) | 41 (60.3) | 63 (58.3) |
Hyperlipidemia, n (%) | 62 (58.5) | 84 (60.0) | 44 (64.7) | 62 (57.4) |
Heart failure, n (%) | 2 (1.9) | 2 (1.4) | 0 (0.0) | 2 (1.9) |
Cerebrovascular disease, n (%) | 4 (3.8) | 12(8.6) | 2 (2.9) | 13 (12.0)* |
Chronic renal failure, n (%) | 2 (1.9) | 9 (6.4) | 1(1.5) | 9 (8.3) |
ASO, n (%) | 5(4.7) | 6 (4.3) | 4 (5.9) | 17 (15.7)* ** |
Chronic obstructive pulmonary disease, n (%) | 2 (1.9) | 5 (3.6) | 1 (1.5) | 1 (0.9) |
Malignancy, n (%) | 4 (3.8) | 11 (7.9) | 3 (4.4) | 3 (2.8) |
   Previous procedures (PTCA/CABG), n (%) | 3 (2.8) | 7 (5.0) | 6 (8.8) | 8 (7.4) |
Laboratory data at the time of admission | ||||
   Fasting blood sugar, mg/dL | 90 ± 7 | 94 ± 9.* | 99 ± 11* ** | |
   Blood sugar after 2 h, mg/dL | 115 ± 18 | 165 ± 20* | 237 ± 30* ** | |
   HbA1c, % | 5.3 ± 0.3 | 5.4 ± 0.5* | 5.7 ± 0.4* ** | 8.1 ± 1.5* ** *** |
   Total Cholesterol, mg/dL | 194 ± 39 | 193 ± 37 | 199 ± 33 | 199 ± 42 |
   Triglyceride, mg/dL | 107 ± 85 | 102 ± 56 | 123 ± 74** | 122 ± 87** |
   LDL-Cholesterol, mg/dL | 130 ± 37 | 130 ± 32 | 129 ± 33 | 130 ± 36 |
   HDL-Cholesterol, mg/dL | 44 ± 11 | 43 ± 12 | 45 ± 20 | 45 ± 12 |
   Serum creatinine, mg/dL | 0.8 ± 0.2 | 0.8 ± 0.3 | 0.8 ± 0.2 | 0.9 ± 0.3 |
   Urea acid, mg/dL | 5.3 ± 1.5 | 5.5 ± 1.6 | 5.6 ± 1.3 | 5.2 ± 1.8 |
Characteristics of acute myocardial infarction | ||||
   Systolic blood pressure on admission, mmHg | 135 ± 25 | 139 ± 23 | 139 ± 24 | 136 ± 24 |
   Heart rate on admission, bpm/m | 72 ± 17 | 75 ± 16 | 76 ± 18 | 77 ± 19 |
   Killip class≦‖, n (%) | 9 (8.5) | 5 (3.6) | 4 (5.9) | 15 (13.9)** |
   Anterior MI, n (%) | 45 (42.5) | 77 (55.0) | 28 (41.2) | 50 (46.3) |
   Multi-vessel disease, n (%) | 48(45.3) | 63 (45.0) | 35 (51.5) | 73 (67.6)* ** *** |
   Procedural features | ||||
Thrombolysis, n (%) | 16 (15.1) | 19 (13.6) | 7 (10.3) | 14 (13.0) |
Primary PTCA/CABG, n (%) | 64(60.4) | 96 (68.6) | 45 (66.2) | 61 (56.5) |
Stent implantation, n (%) | 73(68.9) | 116 (82.9)* | 52 (76.5) | 68 (63.0) |
   LVEF, % | 44.4 ± 8.1 | 42.8 ± 8.2 | 43.9 ± 8.8 | 43.6 ± 9.2 |
   Peak CPK, U/L | 2827 ± 1905 | 2988 ± 2385 | 2741 ± 1588 | 2757 ± 2393 |
Medications | ||||
   Aspirin, n (%) | 103(97.2) | 138 (98.6) | 66 (97.1) | 104 (96.3) |
   ACEI/ARB, n (%) | 72 (67.9) | 104 (74.3) | 54 (79.4) | 73 (67.6) |
   Beta-blockers, n (%) | 46(43.4) | 87(62.1)* | 45 (66.2)* | 63(58.3)* |
   Statin, n (%) | 46 (43.4) | 65 (46.4) | 39 (57.4) | 45 (41.2) |
   Oral hypoglycemic agents, n (%) | 0 (0) | 0 (0) | 2 (2.9) | 66 (61.1)* ** *** |
   Insulin therapy, n (%) | 0 (0) | 0 (0) | 0 (0) | 18 (16.7)* ** *** |